Navigation Links
Study Shows That Roche's Investigational Drug for Alzheimer's Disease Removes Amyloid Plaques From the Brain
Date:10/10/2011

BASEL, Switzerland, Oct. 10, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer's disease. The study "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab" is published today in the October issue of Archives in Neurology.(1)

It is the first time that clinical data has been published for gantenerumab, an investigational compound with a mechanism of action targeted at the early stages of Alzheimer's disease.

Results from Phase I clinical trials and ex vivo studies demonstrated that gantenerumab treatment results in a dose-dependent reduction of brain amyloid, possibly through phagocytosis via brain microglial cells, whereas amyloid load increased in patients receiving placebo treatment.

"These results and especially the rapidity of the effects observed on amyloid removal are very encouraging and pave the way for the development of a novel treatment for Alzheimer's disease," said Luca Santarelli, Global Head of Roche Neuroscience Disease Translational Area. "Our approach is to utilize biomarkers to diagnose and treat the disease at a very early stage before significant damage to the brain has occurred."

Gantenerumab is an investigational fully human anti-amyloid beta monoclonal antibody designed to bind to amyloid plaques in the brain and remove them. It is hoped that this approach will slow progression of the disease, an outcome that cannot be achieved with currently approved treatments.

"Our objective was not only to demonstrate the effects of gantenerumab on brain amyloid, but also to start elucidating its mechanism of action," added Santarelli, "this is extremely important to fully understand the compound's therapeutic potential for Alzheimer's disease."

Since it is known that amyloid accumulate
'/>"/>

SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Hernia Publishes a Unique Three Year Pre-Clinical Study of absorbable TIGR® Matrix Surgical Mesh Versus a Permanent Mesh
2. Hologic Announces Six-year Follow-up Results from the MammoSite Targeted Breast Irradiation Registry Study
3. Bioness Inc. Announces Completion of Enrollment in Its FASTEST L300 Study
4. FDA CONSUMER HEALTH INFORMATION -- Foreign Exporters Study Food Safety Law
5. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
6. Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society
7. Study by Ocala Oncology/The US Oncology Network Shows Use of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Improves Overall Survival
8. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
9. Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients
10. To Succeed in Crowded Market, Diabetes Manufacturers Beginning Key Launch Tactics Earlier, Study Says
11. Swype Cold & Flu Shield Significantly Reduces Occurrence of Colds in Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...   Fruit Street Health (Fruit Street), today ... of funding. The round, which includes ... of individual investors, the majority of whom are prominent ... round are; Houston Cardiology Consultants Partner Asif Ali, ... Rapha Family Medicine Practice Owner Frances Ilozue , ...
(Date:9/18/2014)...  KIYATEC announced today that it has been ... (SBIR) Phase II Contract from the National Cancer ... centers that comprise the National Institutes of Health ... award, KIYATEC will expand its 3D breast cancer ... of cancer therapy strategies: 1) cancer,s interaction with ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group finds ... growth factor (VEGF) agent for wet AMD, is equally ... plans as Genentech,s Lucentis, which is the standard of ... care organization (MCO) directors do not identify a clear ... more likely than Lucentis to be listed on tier ...
Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
(Date:9/18/2014)... (PRWEB) September 18, 2014 CarePoint Health ... removal of a cancerous prostate, along with the adjacent ... new da Vinci robotic Xi platform was performed at ... performed by Dr. Mutahar Ahmed and Dr. Yale Shulman ... and anesthesiologists, specifically trained for robotic procedures. The robot ...
(Date:9/18/2014)... HealthDay Reporter THURSDAY, Sept. ... that testosterone replacement therapy effectively treats normally sagging levels of ... Drug Administration advisory panel said Wednesday. The panel, from ... of the popular drugs and require drug makers to conduct ... according to Bloomberg News . "The whole idea ...
(Date:9/18/2014)... New research led by Queen,s University professor Robert Campbell ... surgery is not helpful or necessary., Glaucoma is the ... and about 400,000 Canadians are afflicted with the disease, ... being high enough to damage the optic nerve. The ... eye to the brain and is a vital part ...
(Date:9/18/2014)... German . In ... fight a pathogen tooth and nail, but rather tolerate it to ... of tolerance is that the disease only progresses very slowly ... pathogen load. , Roland Regoes, a senior scientist at ETH Zurich,s ... He set about investigating whether there are infected people who are ...
(Date:9/18/2014)... September 18, 2014 It is almost time ... or walk for healthier and happier kids. The South ... in the 4th Annual Miami Children’s Hospital 5K Run/Walk. ... http://www.hyundaihopeonwheels.org , The 5K will take place on ... be outside of Coral Gables City Hall located at 405 ...
Breaking Medicine News(10 mins):Health News:CarePoint Health Physicians Perform the First Prostatectomy in New Jersey Using the da Vinci Xi Robot 2Health News:CarePoint Health Physicians Perform the First Prostatectomy in New Jersey Using the da Vinci Xi Robot 3Health News:FDA Panel: Limit Testosterone Drug Use 2Health News:FDA Panel: Limit Testosterone Drug Use 3Health News:FDA Panel: Limit Testosterone Drug Use 4Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3
... get the blues during the course of the winter and ... far more difficult to overcome the seasonal affective disorder (SAD), ... ,Those who suffer from SAD overeat, sleep ... irritability and depression and develop an aversion to social interactions. ...
... associated with several alleged miscarriages of justice has been ... decision has been hailed as one to preserve public ... officials in Saskatchewan have voted to curtail practicing privileges ... Smith. ,Smith had been granted temporary ...
... are reporting that the traditional method of assessing the ... the danger //of missing one-third of women who are ... ,Roger Blumenthal, M.D., an associate professor and ... Johns Hopkins University School of Medicine and its Heart ...
... University of Chicago have announced findings of archeological evidence that ... leading to the destruction of a city. Clemens Reichel, a ... was conducted was a war zone. Artifacts from daily life ... at the Iraqi border. ,The findings prove ...
... milk is so there is study in Australia ... with nutraceutical, pharmaceutical and agrochemical potential.// ... Queensland's Institute for Molecular Bioscience (IMB) and the ... has teamed up with MG Nutritionals for the ...
... Woo Suk the cloning pioneer of South Korea is defending ... editors of Science magazine in Washington to retract his work.//, ... magazine, Donald Kennedy said that Hwang would have 'days or ... his bid to retract a pioneering article that held out ...
Cached Medicine News:Health News:Calcium Levels Could Indicate Future Heart Disease Risk 2Health News:Excavations Reveal Clues Of Early Warfare 2Health News:Scientist Calls Upon Media To Retract His Work 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: